You are here

Publications

Found 64 results
Sort by: Author Title Type [ Year (Desc)]
Filters: Author is B. Haibe-Kains  [Clear All Filters]
2006
Equeter C, Ouriaghli EF, Haibe-Kains B, Stamatopoulos B, André F, Lallemand F, Filippov V, Larsimont D, Sotiriou C, Willard-Gallo K, et al. CD4+ T cells infiltrating breast tumors exhibit altered expression of T cell immune response genes in comparison with their counterparts from the lymph node and blood.
Haibe-Kains B, Sotiriou C, Bontempi G. Class Discovery and Class Prediction from Human Cancer Microarray Datasets.
Sotiriou C, Wirapati P, Loi S, Haibe-Kains B, Desmedt C, Tutt A, Ellis P, Buyse M, Delorenzi M, Piccart M, et al. Comprehensive analysis integrating both clinicopathological and gene expression data in more than 1500 samples: Proliferation captured by gene expression grade index appears to be the strongest prognostic factor in breast cancer (BC).
Sotiriou C, Haibe-Kains B, Desmedt C, Wirapati P, Durbecq V, Harris A, Larsimont D, Bontempi G, Buyse M, Delorenzi M, et al. Comprehensive molecular analysis of several prognostic signatures using molecular indices related to hallmarks of breast cancer: proliferation index appears to be the most significant component of all signatures.
Desmedt C, Azambuja E, Di Leo A, Larsimont D, Durbecq V, Antoine D, Lallemand F, Haibe-Kains B, Cardoso F, Nogaret JM, et al. Gene expression profiling can predict pathological complete response (pCR) to anthracycline-monotherapy in estrogen-receptor (ER) negative breast cancer (BC) patients.
Sotiriou C, Wirapati P, Loi SM, Desmedt C, Durbecq V, Harris A, Bergh J, Smeds J, Haibe-Kains B, Larsimont D, et al. Gene expression profiling in breast cancer: Understanding the molecular basis of histologic grade to improve prognosis. Journal of National Cancer Institute. 2006:262-272.
Sotiriou C, Wirapati P, Loi S, Haibe-Kains B, Piette F, Buyse M, Bontempi G, Delorenzi M, Piccart M. Is genomic grading killing histological grading ?. In: Journal of European Breast Cancer. Vol. 4. Journal of European Breast Cancer. ; 2006. p. 177.
2005
Sotiriou C, Wirapati P, Loi S, Desmedt C, Durbecq V, Harris A, Bergh J, Smeds J, Haibe-Kains B, Larsimont D, et al. Better characterization of estrogen receptor (ER) positive luminal subtypes using genomic grade. In: Breast Cancer Research and Treatment. Vol. 94. Breast Cancer Research and Treatment. ; 2005. p. S19.
Sotiriou C, Wirapati P, Loi SM, Desmedt C, Durbecq V, Harris A, Bergh J, Smeds J, Haibe-Kains B, Larsimont D, et al. Breast tumours with intermediate histological grade can be reclassified into prognostically distinct groups by gene expression profiling. In: Breast Cancer Research and Treatment. Vol. 94. Breast Cancer Research and Treatment. ; 2005. p. S30.
Desmedt C, Loi SM, Haibe-Kains B, Soree A, Lallemand F, Durbecq V, Larsimont D, Tutt A, Ellis P, Gillett C, et al. Four genes by RT-PCR predicts distant relapse for women given adjuvant tamoxifen. In: Breast Cancer Research and Treatment. Vol. 94. Breast Cancer Research and Treatment. ; 2005. p. S129.
Sotiriou C, Wirapati P, Loi S, Harris A, Bergh J, Smeds J, Farmer P, Praz V, Haibe-Kains B, Lallemand F, et al. Gene Expression Profiling in Breast Cancer Challenges the Existence of Intermediate Histological Grade.
Loi S, Desmedt C, Haibe-Kains B, Lallemand F, Gillett C, Tutt A, Ryder K, Ellis P, Harris A, Smeds J, et al. Predicting relapse in estrogen receptor (ER) positive breast cancer (luminal) subgroups treated with adjuvant tamoxifen. In: Breast Cancer Research and Treatment. Vol. 94. Breast Cancer Research and Treatment. ; 2005. p. S129.
Loi S, Piccart M, Haibe-Kains B, Desmedt C, A.Harris, Bergh J, Ellis P, Miller L, Liu E, Sotiriou C, et al. Prediction of early distant relapses on tamoxifen in early- stage breast cancer (BC): a potential tool for adjuvant aromatase inhibitor (AI) tailoring.

Pages

Theme by Danetsoft and Danang Probo Sayekti inspired by Maksimer